Home / Research Library / Waning Immunity after the BNT162b2 Vaccine in Isra...
🧬 Medicine & Biology OpenAlex

Waning Immunity after the BNT162b2 Vaccine in Israel

📅 October 27, 2021 👤 Yair Goldberg, Micha Mandel, Yinon M. Bar-On et al. 📖 New England Journal of Medicine 📊 1,045 citations

🤖 Plain-English Summary

BACKGROUND: In December 2020, Israel began a mass vaccination campaign against coronavirus disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to a sharp curtailing of the outbreak. The rate ratio for severe disease among persons fully vaccinated in the month when they were first eligible, as compared with those fully vaccinated in March, was 1.8 among persons 60 years of age or older and 2.2 among those 40 to 59 years of age; owing to small numbers, the rate ratio could not...

🔑 Key Findings

  • After a period with almost no cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a resurgent Covid-19 outbreak began in mid-June 2021.
  • Possible reasons for the resurgence were reduced vaccine effectiveness against the delta (B.1.617.2) variant and waning immunity.
  • The extent of waning immunity of the vaccine against the delta variant in Israel is unclear.

💡 Why This Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

Read the full paper
Access the original peer-reviewed research via OpenAlex.

View on DOI ↗

📋 Article Details

Category 🧬 Medicine & Biology
Published Oct 27, 2021
Journal New England Journal of Medicine
Authors Yair Goldberg, Micha Mandel, Yinon M. Bar-On, Omri Bodenheimer, Laurence Freedman
DOI 10.1056/nejmoa2114228
Citations 1,045
Source OpenAlex

More 🧬 Medicine & Biology Research